



12-09-05
IAP4 Rec'd PCT/PTO 08 DEC 2005
Attorney Docket No.: E3691-00102

UNITED STATES PATENT AND TRADEMARK OFFICE

In re the Application of)	Group Art Unit: Unknown
)	
Cooper et al.)	Examiner: Unknown
)	
Serial No.: 10/525,345)	Confirmation No.: 3912
)	
Filed: August 20, 2003)	Customer No.: 53897
)	
For: DOSAGE FORMS AND RELATED)	
THERAPIES)	
)	

INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. § 1.97-1.98

Mail Stop Amendment
Commissioner for Patents
P. O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

This Information Disclosure Statement is being filed prior to the first office action on the merits of the above-captioned application, thus, it is believed that no fee is due in connection with this submission. However, if it is determined that a fee is due, the Commissioner is hereby authorized to charge the requisite fee, or any fees that may be due in connection with this and the attached papers, or with this application during its entire pendency, or to credit any overpayment, to Deposit Account No. 04-1679.

In accordance with 37 C.F.R. §1.56 and 37 C.F.R. §§1.97-1.98, this Information Disclosure Statement, including Forms PTO/SB/08 (12 pages), and cited documents, is provided herewith.

CERTIFICATE OF EXPRESS MAILING UNDER 37 C.F.R. §1.10

I hereby certify that this correspondence (along with any paper referred to as being attached) is being mailed via "Express Mail Post Office to Addressee" service of the United States Postal Service (Express Mail No. EV678345867US and EV678345875US December 8, 2005, in an envelope addressed to the Commissioner of Patents, P.O. Box 1450, Alexandria, VA 22313-1450

By: R. P. Ippolito
Rokan Ippolito

Date: December 8, 2005

Applicant would also like to cross-reference the following U.S. and International applications:


<u>U.S. App. Serial. No.</u>	<u>Filing Date</u>	<u>Pub. No.</u>	<u>Pub. Date</u>
09/671,967	09/27/2000	6,348,465	02/19/2002
09/818,344	03/26/2001	6,855,511	02/15/2005
09/975,751	10/10/2001	6,610,693	08/26/2003
10/226,685	08/22/2002	6,897,243	05/24/2005
10/388,213	03/12/2003	2003/0203973	10/30/2003
11/023,827	12/28/2004	2005/0159489	07/21/2005
11/018,720	12/20/2004	2005/0159364	07/21/2005
11/184,761	07/19/2005	Unknown	Unknown
11/221,298	09/07/2005	Unknown	Unknown

<u>International App. No.</u>	<u>Filing Date</u>	<u>Pub. No.</u>	<u>Pub. Date</u>
PCT/NZ99/00161	09/24/1999	WO 00/18392	04/06/2000
PCT/NZ99/00160	09/24/1999	WO 00/18891	04/06/2000
PCT/NZ03/00043	03/10/2003	WO 03/075910	09/18/2003
PCT/NZ03/00042	03/10/2003	WO 03/077901	09/25/2003
PCT/NZ03/00047	03/17/2003	WO 04/017957	03/04/2004
PCT/NZ03/00184	08/20/2003	WO 04/017956	03/04/2004
PCT/NZ04/000325	12/20/2004		

The items identified in this Information Disclosure Statement may or may not be "material" pursuant to 37 C.F.R. §1.56. The filing of this Information Disclosure Statement is not an admission by Applicants or Applicants' representatives that any of the documents, singly or in any combination, is effective as prior art against the subject application. Additionally, in accordance with 37 C.F.R. §1.97(h), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information as defined in 37 C.F.R. §1.56(b) exists in addition to those submitted herewith.

Applicants respectfully request that the Examiner review the foregoing documents and information and that they be made of record in the file history of the subject application.

Respectfully submitted,

By: 
 James W. Collett, Ph.D.
 Reg. No. 46,636

DUANE MORRIS LLP
 101 West Broadway, Suite 900
 San Diego, CA 92101-8285
 (O) (619) 744-2200
 (F) (619) 744-2201

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. E3691-00102	Application No. 10/525,345
Information Disclosure Statement by Applicant (Use several sheets if necessary) (37 CFR §1.902(b))		Applicant Cooper et al.	
		Filing Date 08/20/2003	Group Art Unit Unknown

U.S. Patent Documents

Examiner Initial	Desig. ID	Document Number	Publication Date	Patentee	Class	Subclass	Filing Date If Appropriate
	AA	3791988	02/12/1974	Josef Dieter			
	AB	4374829	02/22/1983	Harris et al			
	AC	4410541	10/18/1983	Kamimae et al.			
	AD	4758583	07/19/1988	Cerami et al.			
	AE	4866090	09/12/1989	Hoffman et al.			
	AF	4952568	08/28/1990	Sawai et al.			
	AG	5077313	12/31/1991	Lubec			
	AH	5128360	07/07/1992	Cerami et al.			
	AI	5246970	09/21/1993	Williamson et al.			
	AJ	5387109	02/07/1995	Ishikawa et al.			
	AK	5852009	12/22/1998	Cerami et al.			
	AL	5980914	11/09/1999	Gerolymatos			
	AM	6147070	11/04/2000	Faccjomo			
	AN	6348465	02/19/2002	Baker			
	AO	6610693	08/26/2003	Baker			
	AP	6821954	11/23/2004	Reid et al.			
	AQ	6855511	02/15/2005	Baker			
	AR	6884575	04/26/2005	Cooper et al.			
	AS	6897243	05/24/2005	Baker et al.			
	AT	6951890	10/04/2005	Cooper et al.			
	AU	2002/0034775	03/21/2002	Baker, J.R.			
	AV	2003/0045506	03/06/2003	Baker, J.R.			
	AW	2003/0055113	03/20/2003	Wang et al.			
	AX	2003/0186946	10/02/2003	Cooper et al.			
	AY	2003/0166561	09/04/2003	Cooper et al.			
	AZ	2003/0203973	10/30/2003	Cooper et al.			
	AAA	2004/0023854	02/05/2004	Cooper et al.			

Examiner Signature	Date Considered
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Substitute Form PTO-1449 (Modified) Information Disclosure Statement by Applicant (Use several sheets if necessary) (37 CFR §1.98(b))	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. E3691-00102	Application No. 10/525,345
	Applicant Cooper et al.		
	Filing Date 08/20/2003	Group Art Unit Unknown	

U.S. Patent Documents							
Examiner Initial	Desig. ID	Document Number	Publication Date	Patentee	Class	Subclass	Filing Date If Appropriate
	ABB	2004/0038861	02/26/2004	Cooper et al.			
	ACC	2004/0142393	07/22/2004	Cooper et al.			
	ADD	20050002876	01/06/2005	Yukl et al.			
	AEE	2005/0159489	07/21/2005	Baker et al.			
	AFF	2005/0159364	07/21/2005	Cooper et al.			
	AGG	2005/0074756	04/07/2005	Cooper et al.			
	AHH	2005/0047998	03/03/2005	Cooper et al.			

Foreign Patent Documents or Published Foreign Patent Applications								
Examiner Initial	Desig. ID	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation	
							Yes	No
	AII	EP 0331014	02/23/1989	Europe				
	AJJ	DE 3217071 A1	11/10/1983	Germany				
	AKK	EP 0426066 A2	05/08/1991	Europe				
	ALL	EP 0 576 838	01/05/1994	Europe				
	AMM	GB 2192789 A	01/27/1988	Europe				
	ANN	GB 2192790 A	01/27/1988	Europe				
	AOO	JP 2000204037	07/25/2000	Japan				
	APP	JP 7118148	05/09/1995	Japan				
	AQQ	P.202419	12/31/1979	Poland				
	ARR	WO 8201804 A	05/27/1982	WIPO				
	ASS	WO 85/04169	09/26/1985	WIPO				
	ATT	WO 87-05505 A1	09/24/1987	WIPO				
	AUU	WO 95/11690	05/04/1995	WIPO				
	AVV	WO 95/17900	07/06/1995	WIPO				
	AWW	WO 96/12483	05/02/1996	WIPO				
	AXX	WO 9840071 A	09/17/1998	WIPO				
	AYY	WO 99/39712 A1	08/12/1999	WIPO				

Examiner Signature	Date Considered
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Substitute Form PTO-1449 (Modified) Information Disclosure Statement by Applicant (Use several sheets if necessary) (37 CFR §1.98(b))	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. E3691-00102	Application No. 10/525,345
	Applicant Cooper et al.		
	Filing Date 08/20/2003	Group Art Unit Unknown	

Foreign Patent Documents or Published Foreign Patent Applications								
Examiner Initial	Desig. ID	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation	
							Yes	No
	AZZ	WO 9945907 A2	09/16/1999	WIPO				
	AAAA	WO 00/18392 A1	04/06/2000	WIPO				
	ABBB	WO 00/18891 A1	04/06/2000	WIPO				
	ACCC	WO0078805A1	12/28/2000	WIPO				
	ADDD	WO2002079785A2	10/10/2002	WIPO				
	AEEE	WO2003045424A1	06/05/2003	WIPO				
	AFFF	WO2003062275A1	07/31/2003	WIPO				
	AGGG	WO2003063880A1	08/07/2003	WIPO				
	AHHH	WO2003074559A1	09/12/2003	WIPO				
	AIII	WO 03/075910 A1	09/18/2003	WIPO				
	AJJJ	WO 03/077901 A1	09/25/2003	WIPO				
	AKKK	WO 03082259 A1	10/09/2003	WIPO				
	ALLL	WO2003093311A1	11/13/2003	WIPO				
	AMMM	WO2004012760A1	02/12/2004	WIPO				
	ANNN	WO2004012761A1	02/12/2004	WIPO				
	AOOO	WO2004017956A1	03/04/2004	WIPO				
	APPP	WO2004017957A1	03/04/2004	WIPO				
	AQQQ	WO2004056861 A2	07/08/2004	WIPO				
	ARRR	WO2004065614 A2	08/05/2004	WIPO				
	ASSS	WO2004083215 A1	09/30/2004	WIPO				
	ATTT	WO2004087160 A1	10/14/2004	WIPO				
	AUUU	WO2005058294 A1	06/30/2005	WIPO				
	AVVV	WO2005040205A1	05/06/2005	WIPO				

Other Documents (include Author, Title, Date, and Place of Publication)		
Examiner Initial	Desig. ID	Document
	AWWW	American Diabetes Association. (1997). "Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus", Diabetes Care 20:1183

Examiner Signature	Date Considered
--------------------	-----------------

EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. E3691-00102	Application No. 10/525,345
Information Disclosure Statement by Applicant (Use several sheets if necessary)		Applicant Cooper et al.	
		Filing Date 08/20/2003	Group Art Unit Unknown
(37 CFR §1.98(b))			

Other Documents (include Author, Title, Date, and Place of Publication)		
Examiner Initial	Desig. ID	Document
	AXXX	American Diabetes Association. (1998). "Economic Consequences of Diabetes Mellitus in the U.S. in 1997", <i>Diabetes Care</i> 21(2):296-309
	AYYY	Anaja, (1997). "Diagnostic performance of red cell sorbitol assay in a Nigerian teaching hospital", <i>Clinica Chimica Acta</i> . 262:1
	AZZZ	Baker, et al. (1993). "Mechanism of fructosamine assay: evidence against role of superoxide as intermediate in nitroblue tetrazolium reduction". <i>Clin Chem</i> . 39(12):2460
	AAAAA	Barthelmebs, M. et al. (1990). "L-Dopa and Streptozotocin-Induced Diabetic Nephropathy in Rats", <i>American Journal of Hypertension</i> 3(6) Part 2:72S-74S
	ABBBB	Barthelmebs, M. et al. (1991). "Effects of Dopamine Pro-drugs and Fenoldopam on Glomerular Hyperfiltration in Streptozotocin-Induced Diabetes in Rats", <i>Journal of Cardiovascular Pharmacology</i> 18(2):243-253
	ACCCC	Barthelmebs, M. et al. (1995). "Pathophysiological Role of Dopamine in the Kidney: Effects in Diabetes Mellitus and after Contralateral Nephrectomy", <i>Hypertens. Res.</i> 18(Suppl. 1):S131-S136
	ADDDD	Baynes, J.W. (1991). "Role of Oxidative Stress in Development of Complications in Diabetes", <i>Diabetes</i> 40:405-412
	AEEEE	Boiadzhieva, N. (1990) "The Effect of Dopaminergic Pharmacological Agents on the Pancreatic Islet Apparatus in Rats", <i>Eksp Med Morfol</i> 29(3):20-26. (English abstract)
	AFFFF	Borgstrom, L. et al. (1986). "Pharmacokinetics of N-Acetylcysteine in Man", <i>Eur J Clin Pharmacol</i> 31:217-222
	AGGGG	Chan, P.C. and Bielski, B.H.J. (1974) "Enzyme-catalyzed Free Radical Reactions with nicotinamide Adenine Nucleotides", <i>J Biol Chem</i> 249(4):1317-1319
	AHHHH	Chan, P.C. and Bielski, B.H.J. (1980). "Glyceraldehyde-3-Phosphate Dehydrogenase-catalyzed Chain Oxidation of Reduced Nicotinamide Adenine Dinucleotide by Perhydroxyl Radicals", <i>J Biol chem</i> 255(3):874-876
	AIIII	Chaturvedi, N. et al. (1998). "Effect of Lisinopril on Progression of Retinopathy in Normotensive People with Type 1 Diabetes", <i>The Lancet</i> 351:28-31
	AJJJJ	Dahlman, et al., (2000). "Long-term treatment of Wilson's disease with triethylene tetramine dihydrochloride (trientine)", <i>YJM</i> 9=88(9):609-616
	AKKKK	Deckert T. et al. (1978). "Prognosis of Diabetics with Diabetes Onset before the Age of Thirtyone", <i>Diabetologia</i> 14:363-370
	ALLLL	Dubois, R.S. et al. (1970). "Triethylene Teramine Dihydrochloride in Wilson's Disease", <i>Lancet</i> 2(7676):775
	AMMMM	Duchin, K.L. et a. (1988). "Pharmacokinetics of Captopril in Healthy Subjects and in Patients with Cardiovascular Diseases", <i>Clin Pharmacokinetics</i> 14:241-259
	ANNNN	Elstner, E.f. and Heupel, A. (1976). "Inhibition of Nitrite Formation from Hydroxylammonium-chloride: A Simple Assay for Superoxide Dismutase", <i>Anal Biochem</i> 70:616-620
	AOOOO	Epstein, O. and Sherlock, S. (1980). "Triethylene Tetramine Dihydrochloride Toxicity in Primary Biliary Cirrhosis", <i>Gastroenterology</i> 78(6):1442-1445
	APPPP	CHIARA ET AL: "Novel Degradation Pathway of Glycated Amino Acids into Free Fructosamine by a Pseudomonas sp. Soil Strain Extract." <i>JOURNAL OF BIOLOGICAL CHEMISTRY</i> , vol. 270, no. 1, 1995, pages 218-224, XP002189588 ISSN: 218-224
	AQQQQ	Greenman, D. et al. (1996). "Subchronic toxicity of triethylenetetramine dihydrochloride in B6C3F1 mice and F344 rats", <i>Fundam. Appl. Toxicol.</i> 29(2):185-193

Examiner Signature	Date Considered
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. E3691-00102	Application No. 10/525,345
Information Disclosure Statement by Applicant (Use several sheets if necessary)		Applicant Cooper et al.	
		Filing Date 08/20/2003	Group Art Unit Unknown
(37 CFR §1.98(b))			

Other Documents (include Author, Title, Date, and Place of Publication)		
Examiner Initial	Desig. ID	Document
	ARRRR	Greenstock, C.L. and Ruddock, G.W. (1976). "Determination of superoxide (O ₂ -) Radical Anion Reaction Rates Using Pulse Radiolysis", <i>Int J Radiat Phys Chem</i> 8:367-369
	ASSSS	Halliwell, B. (1976). "An Attempt to Demonstrate a Reaction between Superoxide and Hydrogen Peroxide", <i>FEBS Lett</i> 72(1):8-10
	ATTTT	Halliwell, B. and Gutteridge, J.M.C. (1989). "Free Radicals in Biology and Medicine", Clarendon Press, Oxford, pp. 136-176
	AUUUU	Haslam, R.H. et al. (1980). "Treatment of Wilson's Disease with Triethylene Tetramine Dihydrochloride," <i>Dev Pharmacol Ther</i> 1 (5):318-324
	AVVVV	Holdiness M.R. (1991). "Clinical Pharmacokinetics of N-Acetylcysteine", <i>Clin Pharmacokinet</i> 20(2):123-124
	AWWWW	Horiuchi, T. et al. (1989). "Purification and Properties of Fructosyl-amino Acid Oxidase from Corynebacterium sp. 2-4-1," <i>Agric Biol Chem</i> 53(1):103-110
	AXXXX	Ido, Y. et al. (1996). "Interactions between the Sorbitol Pathway, Non-enzymatic Glycation, and Diabetic Vascular Dysfunction," <i>Nephrol Dial Transplant</i> 11 [Suppl 5]:72-75
	AYYYY	Karlsson, K. and Marklund, S. L. (1987). "Heparin-induced Release of Extracellular Superoxide Dismutase to Human Blood Plasma," <i>Biochem J</i> 242:55-59
	AZZZZ	Kashihara, N. et al. (1992). "Selective Decreased de novo Synthesis of Glomerular Proteoglycans under the Influence of Reactive Oxygen Species," <i>Proc Natl Acad Sci USA</i> 89:6309-6313
	AAAAAA	Klein, R. et al. (1985). "Retinopathy in Young-onset Diabetic Patients," <i>Diabetes Care</i> 8(4):311-315
	ABBBB	Kodama, H. et al. (1997). "Metabolism of Administered Triethylene Tetramine Dihydrochloride in Humans," <i>Life Sci</i> 61(9):899-907
	ACCCCO	Marklund, S. L. et al. (1982). "Superoxide Dismutase in Extracellular Fluids," <i>Clin Chimica Acta</i> 126:41-51
	ADDDDD	Mattock, M. B. et al. (1998). "Microalbuminuria and Coronary Heart Disease in NIDDM: An Incidence Study," <i>Diabetes</i> 47:1786-1792
	AEEEE	McCord, J. M. and Fridovich, I. (1969). "Superoxide Dismutase: An Enzymic Function for Erythrocyte (Hemocytin)," <i>J Biol Chem</i> 244(22):6049-6055
	AFFFFF	Misra, H. P. and Fridovich, I. (1972). "The Role of Superoxide Anion in the Autoxidation of Epinephrine and a Simple Assay for Superoxide Dismutase," <i>J Biol Chem</i> 247(10):3170-3175
	AGGGGC	Misra, H. P. and Fridovich, I. (1977). "Superoxide Dismutase: 'Positive' Spectrophotometric Assays," <i>Anal Biochem</i> 79:553-560
	AHHHHH	Mizobuchi, N. et al. (1993). "Serum Superoxide Dismutase (SOD) Activity in Diabetes Mellitus," <i>Rinsho Byori</i> 41:673-678. (English Abstract)
	AIIIII	Mogensen, C. E. and Christensen, C. K. (1984). "Predicting Diabetic Nephropathy in Insulin-dependent Patients," <i>New Eng J Med</i> 311(2):89-93
	AJJJJJ	Mogensen, C. E. et al. (1992). "Microalbuminuria in Non-insulin-dependent Diabetes," <i>Clin Nephrol</i> 38 (suppl 1):S28-S38
	AKKKKK	Morita J. et al. (1992). "Wilson's disease treatment by triethylene tetramine dihydrochloride (trientine, 2HClO: long-term observations", <i>Dev. Pharmacol. Ther.</i> 19(1):6-9
	ALLLLL	Morpurgo, L. et al. (1990). "The Role of Copper in Bovine Serum Amine Oxidase," <i>Biol Metals</i> 3:114-117
	AMMMMM	Muchova, J., et al. (1999). "Antioxidant systems in polymorphonuclear leucocytes of type 2 diabetes mellitus", <i>Diabet Med.</i> 16(1):74-78
Examiner Signature		Date Considered
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.		

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. E3691-00102	Application No. 10/525,345
Information Disclosure Statement by Applicant (Use several sheets if necessary) (37 CFR §1.98(b))		Applicant Cooper et al.	
		Filing Date 08/20/2003	Group Art Unit Unknown

Other Documents (include Author, Title, Date, and Place of Publication)		
Examiner Initial	Desig. ID	Document
	ANNNNN	Muruganandam A. et al. (1994). "ELISA for In Vivo Assessment of Nonenzymatically Glycated Platelet Glutathione Peroxidase", Clin. Biochem. 27(4):293-298
	AOOOOO	Obach, R. et al. (1984). "The Pharmacokinetic Profile of Carbidopa in Dogs," J Pharm Pharmacol 36:415-416
	APPPPP	Palcic, M. M. and Janes, S. M. (1995). "Spectrophotometric Detection of Topa Quinone," Meth Enzymol 258:34-38
	AQQQQQ	Pappert, E. J. et al. (1997). "The Stability of Carbidopa in Solution," Movement Disorders 12(4):608-623
	ARRRRR	Picard, S. et al. (1996). "Minimally Oxidised LDL as Estimated by a New Method Increase in Plasma of Type 2 Diabetic Patients with Atherosclerosis of Nephropathy," Diabetes and Metabolism 22(1):25-30
	ASSSSS	Robbins, S. L. et al. (1984). "Pathologic Basis of Disease," 3.sup.rd ed., W. B. Saunders Company: Philadelphia, pp. 991-1061
	ATTTTT	Saeki, H. et al. (1998). "Malignant Syndrome Associated with Disseminated Intravascular Coagulation and a High Level of Amylase in Serum, Followed by Diabetic Coma in an Elderly Patient with Parkinson's Disease during L-Dopa Therapy," Nippon Ronen Igakkai Zasshi 35(2):139-144. (English abstract)
	AUUUUU	Saxena, A. K. et al. (1996). "Purification and Characterization of a Membrane-bound Deglycating Enzyme (1-Deoxyfructosyl Alkyl Amino Acid Oxidase, EC 1.5.3) from a Pseudomonas sp. Soil Strain," J Biol Chem 271(51):32803-32809
	AVVVVV	Siegemund R. et al. "Mode of action of triethylenetetramine dihydrochloride on copper metabolism in Wilson's disease", Acta. Neurol. Scand. 83(6):364-366
	AWWWWW	Skrha, J. et al. (1996). "Relationship of Oxidative Stress and Fibrinolysis in Diabetes Mellitus", Diabet. Med. 13(9):800-805
	AXXXXX	Smith, P. R. and Thornalley, P. J. (1992). "Mechanism of the Degradation of Non-Enzymatically Glycated Proteins under Physiological Conditions," Eur. J. Biochem. 210:729-739
	AYYYYY	Smith, S. A. and Pogson, C. I. (1977). "Tryptophan and the Control of Plasma Glucose Concentrations in the Rat," Biochem J 168(3):495-506
	AZZZZZ	Somani, B., et al. (1999). "Elimination of superoxide dismutase interference in fructosamine assay", Clin. Biochem. 32(3):185-188
	AAAAAA	Sone, H. et al. (1996). "Inhibition of Hereditary Hepatitis and Liver Tumor Development in Long-Evans Cinnamon Rats by the Copper-Chelating Agent Trientine Dihydrochloride," Hepatology 23(4):764-770
	ABBBBB	Sugimoto, H. et al. (1999). "Advanced glycation end products-cytokine-nitric oxide sequence pathway in the development of diabetic nephropathy: aminoguanidine ameliorates the overexpression of tumour necrosis factor-alpha and inducible nitric oxide synthase in diabetic rat glomeruli", diabetologia 42(7):878-886
	ACCCCC	Talseth, T. (1976). "Studies on Hydralazine," European Journal of Clinical Pharmacology 10(6):395-401
	ADDDDD	Talseth, T. (1977). "Kinetics of Hydralazine Elimination," Clinical Pharmacology Therapeutics 21(6):715-720
	AEEEEEE	Tanabe, R. et al. (1996). "Uptake Mechanism of Trientine by Rat Intestinal Brush-border Membrane Vesicles," J Pharm Pharmacol 48:517-521

Examiner Signature	Date Considered
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. E3691-00102	Application No. 10/525,345
Information Disclosure Statement by Applicant (Use several sheets if necessary)		Applicant Cooper et al.	
		Filing Date 08/20/2003	Group Art Unit Unknown
(37 CFR §1.98(b))			

Other Documents (include Author, Title, Date, and Place of Publication)		
Examiner Initial	Desig. ID	Document
	AFFFFFFF	The Diabetes Control and Complications Trial Research Group. (1993). "The Effect of Intensive Treatment of Diabetes on the Development and Progression of Long-term Complications in Insulin-dependent Diabetes Mellitus," N Eng J Med. 329(14):977-986
	AGGGGG	UKPDS Study Organisation. (1998). "Intensive Blood-glucose Control with Sulphonylureas or Insulin Compared with Conventional Treatment and Risk of Complications in Patients with Type 2 Diabetes (UKPDS 33)," Lancet 352:837-853
	AHHHHH	Vailly, B. et al. (1990). "Prevention of L-dopa of Early Renal Consequences of Diabetes Induced by Stepotozocin in Rats," Arch Mal Coeur Vaiss 83(8):1259-1262. (English abstract)
	AIIIIII	Walshe, J. M. (1973). "Copper Chelation in Patients with Wilson's Disease: A Comparison of Penicillamine and Triethylene Tetramine Dihydrochloride," Q J Med New Series, XLII(167):441-452
	AJJJJJ	Walshe, J. M. (1982) "Treatment of Wilson's Disease with Trientine (Triethylene Tetramine) Dihydrochloride," Lancet 8273:643-647
	AKKKKK	Witztum, J. L. (1993). "Role of Oxidised Low Density Lipoprotein in Atherogenesis," Br Heart J 69 (Suppl):S12-S18
	ALLLLL	Wolff, S. P. et al. (1991). "Protein Glycation and Oxidative Stress in Diabetes Mellitus and Ageing," Free Rad Biol Med 10:339-352
	MMMMM	Wynn, J. E. et al. (1970). "The Toxicity and Pharmacodynamics of EGTA: Oral Administration to Rats and Comparisons with EDTA," Toxicol Appl Pharmacol 16:807-817
	ANNNNN	Yanagisawa, T. et al. "Subacute and chronic toxicity studies of triethylenetetramine dihydrochloride (TJA-250) by oral administration to F-344 rats", J. Toxicol. Sci. 23 Suppl. 4:619-642
	AOOOOO	Yucel, D. et al. (1998). "Increased Oxidative Stress in Dilated Cardiomyopathic Heart Failure," Clin Chem 44(1):148-154
	APPPPP	ARMBRUSTER D A: "FRUCTOSAMINE STRUCTURE ANALYSIS AND CLINICAL USEFULNESS" CLINICAL CHEMISTRY, vol. 33, no. 12, 1987, pages 2153-2163, XP001061531 ISSN: 0009-9147
	AQQQQQ	GILLERY P ET AL.: "Glycation of proteins as a source of superoxides" DIABETE METAB, vol. 14, no. 1, 1988, pages 25-30, XP001058074
	ARRRRR	GREEN T AND SHANGGUAN X: "Stoichiometry of O2 Metabolism and NADPH Oxidation of the Cell-free Latent Oxidase Reconstituted from Cytosol and Solubilized Membrane from Resting Human Neutrophils" J. BIOL. CHEM., vol. 268, no. 2, 15 January 1993 (1993-01-15), pages 857-861, XP002192176
	ASSSSS	LAIGHT DW ET AL.: "Microassay of superoxide anion scavenging activity in vitro" ENVIRONMENTAL TOXICOLOGY AND PHARMACOLOGY, vol. 3, 1997, pages 65-68, XP002192177
	ATTTTT	TAKAHASHI MOTOKO ET AL: "Isolation, purification, and characterization of amadoriase isoenzymes (fructosyl amine-oxygen oxidoreductase EC 1.5.3) from Aspergillus sp." JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 272, no. 6, 1997, pages 3437-3443, XP002189585 ISSN: 0021-9258
	AUUUUU	TAKAHASHI MOTOKO ET AL: "Molecular cloning and expression of amadoriase isoenzyme (fructosyl amine:oxygen oxidoreductase, EC 1.5.3) from Aspergillus fumigatus." JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 272, no. 19, 1997, pages 12505-12507, XP002189584 ISSN: 0021-9258

Examiner Signature	Date Considered
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. E3691-00102	Application No. 10/525,345
Information Disclosure Statement by Applicant (Use several sheets if necessary)		Applicant Cooper et al.	
		Filing Date 08/20/2003	Group Art Unit Unknown
(37 CFR §1.98(b))			

Other Documents (include Author, Title, Date, and Place of Publication)		
Examiner Initial	Desig. ID	Document
	AVVVVV	YOSHIDA NOBUYUKI ET AL: "Distribution and properties of fructosyl amino acid oxidase in fungi." APPLIED AND ENVIRONMENTAL MICROBIOLOGY, vol. 61, no. 12, 1995, pages 4487-4489, XP000561863 ISSN: 0099-2240
	WWWWV	Allen, K.G D. et al. (Jan. 1987). "Tetramine Cuprurctic Agents: a Comparison in Dogs", Am. J. Vet. Res. 48(1):28-30
	AXXXXX	Borthwick, T.R. et al. (Apr. 1980). "Copper Chelating Agents: A Comparison of Cuprurctic Responses to Various Tetramines and D-Penicillamine", J. Lab. Clin. Med. 95(4):575-580
	AYYYYY	Cameron, N.E. and Cotter, M.A. (Aug. 1995). "Neurovascular Dysfunction in Diabetic Rats. Potential Contribution of Autoxidation and Free Radicals Examined Using Transition Metal Chelating Agents", J. Clin. Invest. 96(2): 1159-1163
	AZZZZZ	Cameron, N.E. et al. (1995). "Ciliary Neurontrophic Factor Improves Nerve Conduction and Regeneration in Experimental Diabetes," Diabetologia 38(Suppl. 1):A233 Abstract
	AAAAAA	Cohen, N. L. et al. (1983). "The Effect of Copper Chelating Drugs on Liver Iron Mobilization in the Adult Rat," Biochemical and Biophysical Research Communications 113(1):127-134
	ABBBBB	Dwivedi, R. S. et al. (1978). "The Effect of Triethylene Tetramine Upon the Selective Removal of Nickel (II), Iron (II), Manganese (II) and Tin (II) in Rats," Chemosphere 11:925-932
	ACCCCC	Iseki, K. et al. (1992). "Comparison of Disposition Behavior and De-Coppering Effect of Triethylenetetramine in Animal Model for Wilson'S Disease (Long-Evans Cinnamon Rat) with Normal Wistar Rat," Biopharmaceutics & Drug Disposition 13:273-283
	DDDDDD	Keegan, A. et al. (1996). "Transition Metal Chelators and Anti-Oxidants Prevent the Development of Defective Endothelium-Dependent Relaxation in Aortas from Diabetic Rats," Diabetic Medicine 13(Suppl. 1):S17 Abstract
	AEEEEEE	Keegan, A. et al. (Sep. 27, 1999). "Effects of Chelator Treatment on Aorta and Corpus Cavernosum From Diabetic Rats," Free Radical Biology & Medicine 27 (5-6):536-543
	AFFFFFF	Kodama, H. et al. (1997). "Metabolism of Administered Triethylene Tetramine Dihydrochloride in Humans," Life Sciences 61(9):899-907
	GGGGGG	Love, A. et al. (Oct. 24, 1996). "Nerve Function and Regeneration in Diabetic and Galactosaemic Rats: Antioxidant and Metal Chelator Effects," European Journal of Pharmacology 314:33-39
	HHHHHH	McQuaid, A. and Mason, J. (1990). "A Comparison of the Effects of Penicillamine, Trientine, and Trithiomolybdate on [sup.35 S]-labeled Metallothionein In Vitro; Implications for Wilson's Disease Therapy," Journal of Inorganic Biochemistry 41, 87-92
	AIIIIII	Pieper, G. M. et al. (1993). "Hydroxyl Radicals Mediate Injury to Endothelium-Dependent Relaxation in Diabetic Rat," Molecular and Cellular Biochemistry 122:139-145
	AJJJJJJ	Planas-Bohne, F. (1979). "Influence of Several Chelating Agents on the Excretion and Organ Concentration of Copper in the Rat," Toxicology and Applied Pharmacology 50:337-345
	KKKKKK	Shimizu, N. et al. (1997). "Age-Related Copper, Zinc, and Iron Metabolism in Long-Evans Cinnamon Rats and Copper-Eliminating Effects of S-Penicillamine and Trientine-2HCl," The Journal of Trace Elements in Experimental Medicine 10:49-59
	ALLLLLL	Sone, H. et al. (Apr. 1996). "Inhibition of Hereditary Hepatitis and Liver Tumor Development in Long-Evans Cinnamon Rats by the Copper-Chelating Agent Trientine Dihydrochloride," Hepatology 23(4):764-770

Examiner Signature	Date Considered
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. E3691-00102	Application No. 10/525,345
Information Disclosure Statement by Applicant (Use several sheets if necessary) (37 CFR §1.98(b))		Applicant Cooper et al.	
		Filing Date 08/20/2003	Group Art Unit Unknown

Other Documents (include Author, Title, Date, and Place of Publication)		
Examiner Initial	Desig. ID	Document
	MMMMM	Tandon, S. K. et al. (1984). "Effect of Metal Chelators Agent, Trientine, Suppresses Tumor Development and Angiogenesis in the Murine Hepatocellular Carcinoma Cells," Int. J. Cancer 94:768-773
	NNNNN	Appelbaum et al., "The Protective Role of Neocuproine Against Cardiac Damage in Isolated Perfused Rat Hearts", <i>Free Radical Biology & Medicine</i> , vol. 8, pp. 133-143, 1990; Pergamon Press USA
	OOOOO	Beshgetoor et al., "Clinical conditions altering cooper metabolism in humans", Am J Clin Nutr 1998; 67 (suppl):1017S-21S
	APPPPP	Bingham et al., "Characterization of intracellular copper pools in rat hepatocytes using the chelator diamsar", Am. J. Physiol. 272 (Gastrointest. Liver Physiol. 35): G1400-G1407, 1997
	QQQQQ	Brownlee et al., "Aminoguanidine Prevents Diabetes-Induced Arterial Wall Protein Cross-Linking", Science, New Series, vol. 232, No. 4758 (Jun. 27, 1986), 1629-1632
	ARRRRR	Bryszewska et al., "Oxidative Processes in Red Blood Cells from Normal and Diabetic Individuals", <i>Biochemistry and Molecular Biology International</i> , vol. 37, No. 2, 345-354, Oct. 1995
	ASSSSS	Chang et al., "Increased Collagen Cross-Linkages in Experimental Diabetes Reversal by β -Aminopropionitrile and D-Penicillamine", Diabetes, vol. 29, Oct. 1980, 778-781
	ATTTTT	Cooper, "The Action of Mebanazine, a Mono Amine Oxidase Inhibitor Antidepressant Drug in Diabetes", Int. J. Neuropsychiatry, 4:342-5(1966)
	UUUUU	Eklblom, "Potential Therapeutic Value of Drugs Inhibiting Semicarbazide-Sensitive Amine Oxidase: Vascular Cytoprotection in Diabetes Mellitus", Pharmacological Research, vol. 37, No 2, 1998
	VVVVV	Elling, "Penicillamine, Captopril, and Hypoglycemia", Annals of Internal Medicine, vol. 103, No. 4, Oct. 1985
	WWWWW	Hoffken et al., "Excretion of Zinc in Diabetics Receiving Penicillamine", Z Klin Chem Klin Biochem. Jan. 7, 1969; (1):4-7
	XXXXXX	Leinonen et al., "Susceptibility of LDL to oxidation is not associated with the presence of coronary heart disease or renal dysfunction in NIDDM patients", Clinica Chimica Acta 275 (1998) 163-174
	YYYYYY	McArdle et al., "Effect of chelators on copper metabolism and cooper pools in mouse hepatocytes," Am. J. Physiol. 256 (Gastrointest. Liver Physiol. 19): G667-G672, 1989
	AZZZZZ	Norton et al., "Amioguanidine Prevents the Decreased Myocardial Compliance Produced by Streptozotocin-Induced Diabetes Mellitus in Rats", Circulation. 1996;93:1905-1912
	AAAAAA	Ou et al., Thioctic (Lipoic) Acid: A Therapeutic Metal-Chelating Antioxidant?, Biochemical Pharmacology, vol. 50, No. 1, pp.123-126. (1995)
	BBBBBB	Pucheu, et al., "Effect of Iron Overload in the Isolated Ischemic and Reperfused Rat Heart," Cardiovascular Drugs and Therapy, 1993; 7:701-711
	CCCCCC	Rogers et al., "Hydrazine Stress in the Diabetic: Ornithine Decarboxylase Activity", Biochemical Medicine and Metabolic Biology, 40, 46-49 (1988)
	DDDDDD	Salonen et al., Serum Copper and the Risk of Acute Myocardial Infarction: A Prospective Population Study in Men in Eastern Finland, Am. J. Epidemiol, 1991; 134: 268-76
	EEEEEE	Saunders, "The Effects of Excess Renal Copper on Kidney Function in the Diabetic Rat", Research Communications in Chemical Pathology and Pharmacology, vol. 52, No. 1, Apr. 1986, 45-49
	AFFFFFF	Sugimoto et al., "Effects of Aminoguanidine on Structural Alterations of Microvessels in Peripheral Nerve of Streptozotocin Diabetic Rats", Microvascular Research 53, 105-112 (1997)

Examiner Signature	Date Considered
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. E3691-00102	Application No. 10/525,345
Information Disclosure Statement by Applicant (Use several sheets if necessary) (37 CFR §1.98(b))		Applicant Cooper et al.	
		Filing Date 08/20/2003	Group Art Unit Unknown

Other Documents (include Author, Title, Date, and Place of Publication)		
Examiner Initial	Desig. ID	Document
	GGGGGG	Tessier et al., "Effect of pH, phosphate and copper on the interaction of glucose with albumin", <i>Glyconjugate Journal</i> 15, 571-574 (1998), U.K.
	HHHHHH	Vesely et al., "New Strategies in the Prevention and Management of Diabetes and Its Complications," <i>Online Journal, Jacksonville Medicine</i> : May 1997. http://www.onlinejournal.com
	IIIIIIII	Walter et al., "Copper, Zinc, Manganese, and Magnesium Status and Complications of Diabetes Mellitus", <i>Diabetes Care</i> , vol. 14, No. 11, Nov. 1991
	AJJJJJJJ	Wolff, "Diabetes Mellitus and Free Radicals", <i>The British Council</i> (1993), vol. 49, No. 3 pp. 642-652
	KKKKKK	Yagihashi et al., "Effect of Aminoguanidine on Functional and Structural Abnormalities in peripheral Nerve of STZ-Induced Diabetic Rats", <i>Diabetes</i> , vol. 41, Jan. 1992, 47-52
	LLLLLLI	Young et al., "The Effects of Desferrioxamine and Ascorbate on Oxidative Stress in the Streptozotocin Diabetic Rat", <i>Free Radical Biology & Medicine</i> , vol. 18, No. 5, pp. 833-840, 1995
	MMMMMM	Yu et al., "Aminoguanidine inhibits semicarbazide-sensitive amine oxidase activity: implications for advanced glycation and diabetic complications", <i>Diabetologia</i> (1997) 40: 1243-1250
	NNNNNN	Yoshii, J. et al. (2001). "The Copper-Chelating Agent, Trientine, Suppresses Tumor Development and Angiogenesis in the Murine Hepatocellular Carcinoma Cells," <i>Int. J. Cancer</i> 94:768-773
	OOOOOO	Gerhardinger, C. et al. (1995). "Novel Degradation Pathway of Glycated Amino Acids into Free Fructosamine by a <i>Pseudomonas</i> sp. Soil Strain Extract," <i>J Biol Chem</i> 270(1):218-224
	APPPPPP	Encyclopedia of Toxicology, vol. 1, Philip Wexler, ed. published 1998 by Academic Press (San Diego) pp. 376-378
	QQQQQQ	Pasterkamp & Falk, "Atherosclerotic Plaque Rupture: an Overview," <i>J. Clin. Basic Cardiol.</i> 3:81-86 (2000)
	RRRRRR	Baynes, "Role of Oxidative Stress in Development of Complications in Diabetes", <i>Diabetes</i> , vol. 40, Apr. 1991
	ASSSSSS	Berenshtein et al., "Roles of Ferritin and Iron in Ischemic Preconditioning of the Heart", <i>Molecular and Cellular Biochemistry</i> , 234/235: 283-292, 2002; Kluwer Academic Publishers, Netherlands
	TTTTTT	Duffy et al., "Iron Chelation Improves Endothelial Function in Patients with Coronary Artery Disease", <i>Circulation</i> . 2001; 103:2799-28204
	JUUUUU	Howes et al., "Role of Stored Iron in Atherosclerosis", <i>Journal of Vascular Nursing</i> , vol. XVIII, No. 4, 109-114, no date available
	VVVVVV	Hunt et al., "Ascorbic Acid Oxidation: a Potential Cause of the Elevated Severity of Atherosclerosis in Diabetes Mellitus?", <i>FEBS</i> 11659, vol. 311, No. 2, 161-164, no date available
	WWWWW	Walshe, "Triethylene Tetramine Dihydrochloride in Wilson's Disease", <i>Lancet</i> , 1969, ii, 1401
	XXXXXX	CHERNY R.A. ET AL: 'Chelation and Interaction: Complementary Properties in a Compound for the Treatment of Alzheimer's Disease' <i>J STRUCT BIOL.</i> vol. 130, no. 23, June 2000, pages 209 - 216
	YYYYYY	NORGA K. ET AL: 'Prevention of Acute Autoimmune Encephalomyelitis and Abrogation of Relapses in Murine Models of Multiple Sclerosis by the Protease inhibitor D-Penicillamine' <i>INFLAMM RES.</i> vol. 44, no. 12, December 1995, pages 529 - 534
	ZZZZZZ	BREM S.: 'Angiogenesis and Cancer Control: From Concept to Therapeutic Trial' <i>CANCER CONTROL</i> vol. 6, no. 5, October 1999, pages 436 - 458

Examiner Signature	Date Considered
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. E3691-00102	Application No. 10/525,345
Information Disclosure Statement by Applicant (Use several sheets if necessary) (37 CFR §1.98(b))		Applicant Cooper et al.	
		Filing Date 08/20/2003	Group Art Unit Unknown

Other Documents (include Author, Title, Date, and Place of Publication)

Examiner Initial	Desig. ID	Document
	AAAAAA	ROSSI L. ET AL: 'Increased Susceptibility of Copper- Deficient Neuroblastoma Cells to Oxidative Stress-Mediated Apoptosis' FREE RADIC BIOL MED. vol. 30, no. 10, 15 May 2001, pages 1177 – 1187
	BBBBBB	Chemistry Abstracts Registry numbers 4429-04-3, 57-48-7, 1 854-25-7
	CCCCCC	Konarkowska B, Aitken JF, Kistler J, Zhang S, Cooper GJ., Thiol reducing compounds prevent human amylin-evoked cytotoxicity, FEBS J. 2005 Oct;272(19):4949-59
	DDDDDD	Cooper GJ, et al., Demonstration of a hyperglycemia-driven pathogenic abnormality of copper homeostasis in diabetes and its reversibility by selective chelation: quantitative comparisons between the biology of copper and eight other nutritionally essential elements in normal and diabetic individuals, Diabetes. 2005 May;54(5):1468-76
	EEEEEE	Xu A et al., Testosterone selectively reduces the high molecular weight form of adiponectin by inhibiting its secretion from adipocytes, J Biol Chem. 2005 May 6;280(18):18073-80. Epub 2005 May 6
	FFFFFF	Wang Y et al., Adiponectin inhibits cell proliferation by interacting with several growth factors in an oligomerization-dependent manner, J Biol Chem. 2005 May 6;280(18):18341-7. Epub 2005 Feb 25
	GGGGGG	Wang Y et al., Proteomic and functional characterization of endogenous adiponectin purified from fetal bovine serum, Proteomics. 2004 Dec;4(12):3933-42
	HHHHHH	Cooper GJ et al., Regeneration of the heart in diabetes by selective copper chelation, Diabetes. 2004 Sep;53(9):2501-8
	IIIIIIII	Xu A et al, Chronic treatment with growth hormone stimulates adiponectin gene expression in 3T3-L1 adipocytes, FEBS Lett. 2004 Aug 13;572(1-3):129-34
	AJJJJJJJ	Xu A. et al., The fat-derived hormone adiponectin alleviates alcoholic and nonalcoholic fatty liver diseases in mice, J Clin Invest. 2003 Jul;112(1):91-100
	KKKKKK	Aitken JF et al., Suppression by polycyclic compounds of the conversion of human amylin into insoluble amyloid, Biochem J. 2003 Sep 15;374(Pt 3):779-84
	LLLLLLL	Xu A et al, Identification of novel putative membrane proteins selectively expressed during adipose conversion of 3T3-L1 cells, Biochem Biophys Res Commun. 2002 May 17;293(4):1161-7
	MMMMMM	Wang Y et al., Hydroxylation and glycosylation of the four conserved lysine residues in the collagenous domain of adiponectin. Potential role in the modulation of its insulin-sensitizing activity, J Biol Chem. 2002 May 31;277(22):19521-9. Epub 2002 Mar 23
	NNNNNN	Buchanan CM et al., Preptin derived from proinsulin-like growth factor II (proIGF-II) is secreted from pancreatic islet beta-cells and enhances insulin secretion, Biochem J. 2001 Dec 1;360(Pt 2):431-9
	OOOOOO	Cornish J et al., Effects of calcitonin, amylin, and calcitonin gene-related peptide on osteoclast development, Bone. 2001 Aug;29(2):162-8
	PPPPPP	Wang Y et al., Alteration in phosphorylation of P20 is associated with insulin resistance, Diabetes. 2001 Aug;50(8):1821-7
	QQQQQQ	Wang Y et al., Phosphorylation of P20 is associated with the actions of insulin in rat skeletal and smooth muscle, Biochem J. 1999 Dec 15;344 Pt 3:971-6
	RRRRRR	Wang Y et al., Insulin and insulin antagonists evoke phosphorylation of P20 at serine 157 and serine 16 respectively in rat skeletal muscle, FEBS Lett. 1999 Nov 26;462(1-2):25-30

Examiner Signature	Date Considered
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. E3691-00102	Application No. 10/525,345
Information Disclosure Statement by Applicant (Use several sheets if necessary) (37 CFR §1.98(b))		Applicant Cooper et al.	
		Filing Date 08/20/2003	Group Art Unit Unknown

Other Documents (include Author, Title, Date, and Place of Publication)		
Examiner Initial	Desig. ID	Document
	SSSSSSS	Wang Y et al., Amylin evokes phosphorylation of P20 in rat skeletal muscle, FEBS Lett. 1999 Aug 20;457(1):149-52
	TTTTTTT	Cooper GJ et al., Amylin, amyloid and age-related disease, Drugs Aging. 1996 Sep;9(3):202-12
	UUUUUUU	Cooper GJ, Amylin and insulin co-replacement therapy for insulin-dependent (type I) diabetes mellitus, Med Hypotheses. 1991 Nov;36(3):284-8
	VVVVVVV	Leighton B et al., Pancreatic amylin and calcitonin gene-related peptide cause resistance to insulin in skeletal muscle in vitro, Nature. 1988 Oct 13;335(6191):632-5
	WWWWW	Witek E., et al., "Polycondensation of polyethylenepolyamines with aliphatic dicarboxylic acids", Polymers-Large Molecule Materials, The Institute of Polymers, The Lodz Polytechnic, 1976

Examiner Signature	Date Considered
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	